BIONOMICS LIMITED - Announcements

0.00%

1.0¢

Currently unlisted.

Bionomics Limited (Bionomics) is an Australia-bases clinical-stage biopharmaceutical... Bionomics Limited (Bionomics) is an Australia-bases clinical-stage biopharmaceutical company. The Company is focused on developing a pipeline of novel, ion channel targeting drug candidates designed to transform the lives of patients suffering from serious central nervous system (CNS) disorders. The Company operates in drug development segment in Australia. The Company is advancing its lead drug candidate, BNC210, which is an oral, proprietary, selective negative allosteric modulator of the a7 nicotinic acetylcholine receptor, for the acute treatment of Social Anxiety Disorder (SAD) and chronic treatment of Post-Traumatic Stress Disorder (PTSD). The Company has two drugs in early-stage clinical trials for the treatment of cognitive deficits in Alzheimer’s disease and other central nervous system conditions.More

ASX:PAR

This stock could have something close to a cure for osteoarthritis. Paradigm Biopharmaceuticals (ASX:PAR) is a late-stage drug development company working first and foremost to create a superior treatment for osteoarthritis.

Announcements

Filter Results

All Price Sensitive Only

Filters [Clear]

Price Sensitive: Yes

BNO	Underwritten Rights Issue Offer Booklet	PRICE SENSITIVE	04/03/13	221.02KB	Share
BNO	Underwritten Rights Issue to Raise $16.4 Million	PRICE SENSITIVE	04/03/13	61.52KB	Share
BNO	Trading Halt	PRICE SENSITIVE	28/02/13	138.68KB	Share
BNO	Half Yearly Report and Accounts	PRICE SENSITIVE	14/02/13	218.59KB	Share
BNO	BNO Provides BNC101 Update at US Cancer Stem Cell Conference	PRICE SENSITIVE	11/02/13	36.77KB	Share
BNO	BNC375 Alzheimer's Disease Data Presented at Conference	PRICE SENSITIVE	04/02/13	83.51KB	Share
BNO	Appendix 4C - quarterly	PRICE SENSITIVE	31/01/13	72.19KB	Share
BNO	Bionomics R&D Tax Incentive for FY2012	PRICE SENSITIVE	15/01/13	45.99KB	Share
BNO	CEO Update and US Investor Presentation	PRICE SENSITIVE	09/01/13	54.69KB	Share
BNO	BNC210 US TRIAL	PRICE SENSITIVE	21/12/12	46.7KB	Share
BNO	Bionomics New Alzheimer's Drug Candidate	PRICE SENSITIVE	14/12/12	94.42KB	Share
BNO	CEO & Managing Director AGM Presentation 2012	PRICE SENSITIVE	14/11/12	388.61KB	Share
BNO	IND Submission to FDA for BNC210 Anti-Anxiety Drug Candidate	PRICE SENSITIVE	08/11/12	47.58KB	Share
BNO	Appendix 4C - quarterly	PRICE SENSITIVE	31/10/12	38.38KB	Share
BNO	ALPHA 7 PROGRAM TO BE SHOWCASED AT NEUROSCIENCE 2012	PRICE SENSITIVE	16/10/12	90.99KB	Share
BNO	Bionomics Acquires US-Based Cancer Stem Cell Company	PRICE SENSITIVE	17/09/12	43.28KB	Share
BNO	FDA Approval for Ironwood	PRICE SENSITIVE	31/08/12	28.64KB	Share
BNO	Bionomics' 2011/2012 Preliminary Final Results	PRICE SENSITIVE	15/08/12	57.53KB	Share
BNO	Bionomics Secures Key US Patent for VDA BNC105	PRICE SENSITIVE	15/08/12	36.09KB	Share
BNO	Appendix 4C - quarterly	PRICE SENSITIVE	30/07/12	38.07KB	Share
BNO	Open Briefing - CEO on Kv1.3 Program and Outlook	PRICE SENSITIVE	27/06/12	196.67KB	Share
BNO	US Patent Granted for Kv1.3 Program	PRICE SENSITIVE	26/06/12	34.98KB	Share
BNO	Bionomics to Expand KV1.3 Program	PRICE SENSITIVE	15/06/12	37.91KB	Share
BNO	BNC105 Trial Data Presented at ASCO	PRICE SENSITIVE	01/06/12	43.57KB	Share
BNO	Bionomics Launches BNC105 Ovarian Cancer Trial	PRICE SENSITIVE	24/05/12	47.41KB	Share
BNO	Appendix 4C - quarterly	PRICE SENSITIVE	30/04/12	38.12KB	Share
BNO	Open Briefing - CEO on BNC105 Ovarian Cancer Trial	PRICE SENSITIVE	03/04/12	208.24KB	Share
BNO	BNC105 Ovarian Cancer Progress	PRICE SENSITIVE	02/04/12	41.94KB	Share
BNO	BNC105 Ovarian Cancer Trial Approved	PRICE SENSITIVE	23/03/12	42.41KB	Share
BNO	Bionomics Targets Alzheimer's Disease	PRICE SENSITIVE	16/02/12	101.46KB	Share
BNO	Half Yearly Report and Accounts	PRICE SENSITIVE	14/02/12	397.42KB	Share
BNO	BNC105 Renal Cancer Trial Data Presented at ASCO-GU	PRICE SENSITIVE	03/02/12	41.05KB	Share
BNO	Appendix 4C - quarterly	PRICE SENSITIVE	31/01/12	70.91KB	Share
BNO	Ironwood and Bionomics Announce Agreement	PRICE SENSITIVE	05/01/12	211.42KB	Share
BNO	Trading Halt	PRICE SENSITIVE	04/01/12	292.83KB	Share
BNO	BNC210 Clinical Data Presented at Neuroscience 2011	PRICE SENSITIVE	15/11/11	31.25KB	Share
BNO	Appendix 4C - quarterly	PRICE SENSITIVE	28/10/11	38.06KB	Share
BNO	BNC105 Renal Cancer Trial Update	PRICE SENSITIVE	20/09/11	55.16KB	Share
BNO	Bionomics' 2010/2011 Preliminary Final Results	PRICE SENSITIVE	18/08/11	96.41KB	Share
BNO	BNC105 Clinical Trials Reach Key Milestones	PRICE SENSITIVE	03/08/11	46.55KB	Share
BNO	Trading Halt	PRICE SENSITIVE	01/08/11	40.19KB	Share
BNO	Appendix 4C - quarterly	PRICE SENSITIVE	29/07/11	42.04KB	Share
BNO	Phase I BNC105 Clinical Trial Published	PRICE SENSITIVE	23/06/11	36.2KB	Share
BNO	Merck Serono Extends MS Collaboration with Bionomics	PRICE SENSITIVE	09/06/11	34.16KB	Share
BNO	BNC105 Renal Cancer Trial To Be Presented AT ASCO	PRICE SENSITIVE	03/06/11	26.51KB	Share
BNO	Open Briefing - Outlook and Strategic Focus	PRICE SENSITIVE	25/05/11	203.47KB	Share
BNO	Successful Register Repositioning Complete	PRICE SENSITIVE	13/05/11	33.45KB	Share
BNO	Trading Halt	PRICE SENSITIVE	12/05/11	33.48KB	Share
BNO	Start-up Australia Ventures Sells 60 Millions BNO Shares	PRICE SENSITIVE	12/05/11	42.94KB	Share
BNO	BNC210 - Further Validation	PRICE SENSITIVE	10/05/11	42.03KB	Share
BNO	BNO Sells Thebarton Premises to Boost Cash Reserves	PRICE SENSITIVE	04/05/11	22.47KB	Share
BNO	Appendix 4C - quarterly	PRICE SENSITIVE	29/04/11	16.53KB	Share
BNO	Response to ASX Price Query	PRICE SENSITIVE	13/04/11	99.24KB	Share
BNO	Invitation to Tender for Shares	PRICE SENSITIVE	30/03/11	24.33KB	Share
BNO	Anti-Anxiety Drug Clinical Trials Successful Results	PRICE SENSITIVE	30/03/11	160.67KB	Share
BNO	Trading Halt	PRICE SENSITIVE	28/03/11	43.09KB	Share
BNO	Half Yearly Report and Accounts	PRICE SENSITIVE	11/02/11	752.24KB	Share
BNO	Patent Applications Filed on Compounds to Treat Memory Loss	PRICE SENSITIVE	04/02/11	37.63KB	Share
BNO	Appendix 4C - quarterly	PRICE SENSITIVE	31/01/11	16.66KB	Share
BNO	Open Briefing - CEO on Company Update and BNC210 Results	PRICE SENSITIVE	25/11/10	191.13KB	Share
BNO	Invitation to tender for the purchase of 27.76% of shares	PRICE SENSITIVE	10/11/10	90.78KB	Share
BNO	Appendix 4C - quarterly	PRICE SENSITIVE	27/10/10	16.18KB	Share
BNO	BNC210 - European Approval Granted for Two Phase Ib Trials	PRICE SENSITIVE	05/10/10	67.55KB	Share
BNO	Open Briefing - BNO CEO on BNC210 Clinical Trials	PRICE SENSITIVE	02/09/10	191.58KB	Share
BNO	BNC210 Data Presented at Leading European Forum	PRICE SENSITIVE	30/08/10	61.64KB	Share
BNO	Full Year Statutory Accounts	PRICE SENSITIVE	19/08/10	81.95KB	Share
BNO	Appendix 4C - quarterly	PRICE SENSITIVE	19/07/10	17KB	Share
BNO	BNC210 Phase I Trial Successful	PRICE SENSITIVE	21/06/10	69.67KB	Share
BNO	Bionomics Presents BNC105 Clinical Data at ASCO	PRICE SENSITIVE	07/06/10	36.59KB	Share
BNO	Open Briefing - CEO on Merck Serono Extension	PRICE SENSITIVE	25/05/10	223.72KB	Share
BNO	Merck Serono Agreement Extended	PRICE SENSITIVE	24/05/10	35.05KB	Share
BNO	Second BNC210 Phase I Clinical Trial Commences	PRICE SENSITIVE	06/05/10	37.71KB	Share
BNO	Appendix 4C - quarterly	PRICE SENSITIVE	21/04/10	17KB	Share
BNO	New BNC105 Data Presented at International Cancer Conference	PRICE SENSITIVE	16/04/10	38.1KB	Share
BNO	Open Briefing - CEO on Clinical Trials Update	PRICE SENSITIVE	31/03/10	191.87KB	Share
BNO	BNC105 Phase II Mesothelioma Clinical Trial Starts	PRICE SENSITIVE	26/03/10	39.57KB	Share
BNO	BNC210 Clinical Trial Results	PRICE SENSITIVE	02/03/10	49.35KB	Share
BNO	Half Yearly Report and Accounts	PRICE SENSITIVE	18/02/10	1.36MB	Share
BNO	Positive New BNC210 Data	PRICE SENSITIVE	02/02/10	1011.93KB	Share
BNO	Appendix 4C - quarterly	PRICE SENSITIVE	28/01/10	16.95KB	Share
BNO	BNC105 US Renal Cancer Trial Initiated	PRICE SENSITIVE	27/01/10	40.07KB	Share
BNO	Open Briefing - BNC105 Phase II Trial for Mesothelioma	PRICE SENSITIVE	22/12/09	227.91KB	Share
BNO	BNO to Conduct Phase II Trial in Mesothelioma	PRICE SENSITIVE	09/12/09	36.98KB	Share
BNO	Appendix 4C - quarterly	PRICE SENSITIVE	29/10/09	80.91KB	Share
BNO	First Stage of BNC210 Clinical Trial Successfully Completed	PRICE SENSITIVE	27/10/09	35.89KB	Share
BNO	Latest BNC210 Data To Be Presented In US	PRICE SENSITIVE	16/10/09	180.05KB	Share
BNO	CEO Open Briefing	PRICE SENSITIVE	17/09/09	59.64KB	Share
BNO	Reinstatement to Official Quotation	PRICE SENSITIVE	08/09/09	8.03KB	Share
BNO	$15 Million Capital Raising	PRICE SENSITIVE	08/09/09	34.63KB	Share
BNO	Suspension from Official Quotation	PRICE SENSITIVE	07/09/09	17.49KB	Share
BNO	Trading Halt	PRICE SENSITIVE	03/09/09	20.63KB	Share
BNO	Preliminary Final Report - Appendix 4E	PRICE SENSITIVE	28/08/09	76.16KB	Share
BNO	Appendix 4C - quarterly	PRICE SENSITIVE	29/07/09	79.39KB	Share
BNO	Open Briefing - BNO CEO on Milestones Achieved	PRICE SENSITIVE	02/07/09	63.12KB	Share
BNO	BNO - US Clinical Trial of BNC105 in Renal Cell Cancer	PRICE SENSITIVE	02/07/09	28.28KB	Share
BNO	BNC210 Phase I Clinical Trial Initiated	PRICE SENSITIVE	25/06/09	36.81KB	Share
BNO	Open Briefing BNC105 Interim Data	PRICE SENSITIVE	29/05/09	59.92KB	Share
BNO	Initial Data from BNC105 Phase I Clinical Trial Presented	PRICE SENSITIVE	29/05/09	25.46KB	Share
BNO	BNO Anxiety Drug Candidate Approved to Enter Human Trial	PRICE SENSITIVE	21/05/09	25.85KB	Share
BNO	Open Briefing - New Data on BNC105	PRICE SENSITIVE	22/04/09	58.2KB	Share

BNOUnderwritten Rights Issue Offer Booklet
04/03/13	PRICE SENSITIVE	221.02KB	Share
BNOUnderwritten Rights Issue to Raise $16.4 Million
04/03/13	PRICE SENSITIVE	61.52KB	Share
BNOTrading Halt
28/02/13	PRICE SENSITIVE	138.68KB	Share
BNOHalf Yearly Report and Accounts
14/02/13	PRICE SENSITIVE	218.59KB	Share
BNOBNO Provides BNC101 Update at US Cancer Stem Cell Conference
11/02/13	PRICE SENSITIVE	36.77KB	Share
BNOBNC375 Alzheimer's Disease Data Presented at Conference
04/02/13	PRICE SENSITIVE	83.51KB	Share
BNOAppendix 4C - quarterly
31/01/13	PRICE SENSITIVE	72.19KB	Share
BNOBionomics R&D Tax Incentive for FY2012
15/01/13	PRICE SENSITIVE	45.99KB	Share
BNOCEO Update and US Investor Presentation
09/01/13	PRICE SENSITIVE	54.69KB	Share
BNOBNC210 US TRIAL
21/12/12	PRICE SENSITIVE	46.7KB	Share
BNOBionomics New Alzheimer's Drug Candidate
14/12/12	PRICE SENSITIVE	94.42KB	Share
BNOCEO & Managing Director AGM Presentation 2012
14/11/12	PRICE SENSITIVE	388.61KB	Share
BNOIND Submission to FDA for BNC210 Anti-Anxiety Drug Candidate
08/11/12	PRICE SENSITIVE	47.58KB	Share
BNOAppendix 4C - quarterly
31/10/12	PRICE SENSITIVE	38.38KB	Share
BNOALPHA 7 PROGRAM TO BE SHOWCASED AT NEUROSCIENCE 2012
16/10/12	PRICE SENSITIVE	90.99KB	Share
BNOBionomics Acquires US-Based Cancer Stem Cell Company
17/09/12	PRICE SENSITIVE	43.28KB	Share
BNOFDA Approval for Ironwood
31/08/12	PRICE SENSITIVE	28.64KB	Share
BNOBionomics' 2011/2012 Preliminary Final Results
15/08/12	PRICE SENSITIVE	57.53KB	Share
BNOBionomics Secures Key US Patent for VDA BNC105
15/08/12	PRICE SENSITIVE	36.09KB	Share
BNOAppendix 4C - quarterly
30/07/12	PRICE SENSITIVE	38.07KB	Share
BNOOpen Briefing - CEO on Kv1.3 Program and Outlook
27/06/12	PRICE SENSITIVE	196.67KB	Share
BNOUS Patent Granted for Kv1.3 Program
26/06/12	PRICE SENSITIVE	34.98KB	Share
BNOBionomics to Expand KV1.3 Program
15/06/12	PRICE SENSITIVE	37.91KB	Share
BNOBNC105 Trial Data Presented at ASCO
01/06/12	PRICE SENSITIVE	43.57KB	Share
BNOBionomics Launches BNC105 Ovarian Cancer Trial
24/05/12	PRICE SENSITIVE	47.41KB	Share
BNOAppendix 4C - quarterly
30/04/12	PRICE SENSITIVE	38.12KB	Share
BNOOpen Briefing - CEO on BNC105 Ovarian Cancer Trial
03/04/12	PRICE SENSITIVE	208.24KB	Share
BNOBNC105 Ovarian Cancer Progress
02/04/12	PRICE SENSITIVE	41.94KB	Share
BNOBNC105 Ovarian Cancer Trial Approved
23/03/12	PRICE SENSITIVE	42.41KB	Share
BNOBionomics Targets Alzheimer's Disease
16/02/12	PRICE SENSITIVE	101.46KB	Share
BNOHalf Yearly Report and Accounts
14/02/12	PRICE SENSITIVE	397.42KB	Share
BNOBNC105 Renal Cancer Trial Data Presented at ASCO-GU
03/02/12	PRICE SENSITIVE	41.05KB	Share
BNOAppendix 4C - quarterly
31/01/12	PRICE SENSITIVE	70.91KB	Share
BNOIronwood and Bionomics Announce Agreement
05/01/12	PRICE SENSITIVE	211.42KB	Share
BNOTrading Halt
04/01/12	PRICE SENSITIVE	292.83KB	Share
BNOBNC210 Clinical Data Presented at Neuroscience 2011
15/11/11	PRICE SENSITIVE	31.25KB	Share
BNOAppendix 4C - quarterly
28/10/11	PRICE SENSITIVE	38.06KB	Share
BNOBNC105 Renal Cancer Trial Update
20/09/11	PRICE SENSITIVE	55.16KB	Share
BNOBionomics' 2010/2011 Preliminary Final Results
18/08/11	PRICE SENSITIVE	96.41KB	Share
BNOBNC105 Clinical Trials Reach Key Milestones
03/08/11	PRICE SENSITIVE	46.55KB	Share
BNOTrading Halt
01/08/11	PRICE SENSITIVE	40.19KB	Share
BNOAppendix 4C - quarterly
29/07/11	PRICE SENSITIVE	42.04KB	Share
BNOPhase I BNC105 Clinical Trial Published
23/06/11	PRICE SENSITIVE	36.2KB	Share
BNOMerck Serono Extends MS Collaboration with Bionomics
09/06/11	PRICE SENSITIVE	34.16KB	Share
BNOBNC105 Renal Cancer Trial To Be Presented AT ASCO
03/06/11	PRICE SENSITIVE	26.51KB	Share
BNOOpen Briefing - Outlook and Strategic Focus
25/05/11	PRICE SENSITIVE	203.47KB	Share
BNOSuccessful Register Repositioning Complete
13/05/11	PRICE SENSITIVE	33.45KB	Share
BNOTrading Halt
12/05/11	PRICE SENSITIVE	33.48KB	Share
BNOStart-up Australia Ventures Sells 60 Millions BNO Shares
12/05/11	PRICE SENSITIVE	42.94KB	Share
BNOBNC210 - Further Validation
10/05/11	PRICE SENSITIVE	42.03KB	Share
BNOBNO Sells Thebarton Premises to Boost Cash Reserves
04/05/11	PRICE SENSITIVE	22.47KB	Share
BNOAppendix 4C - quarterly
29/04/11	PRICE SENSITIVE	16.53KB	Share
BNOResponse to ASX Price Query
13/04/11	PRICE SENSITIVE	99.24KB	Share
BNOInvitation to Tender for Shares
30/03/11	PRICE SENSITIVE	24.33KB	Share
BNOAnti-Anxiety Drug Clinical Trials Successful Results
30/03/11	PRICE SENSITIVE	160.67KB	Share
BNOTrading Halt
28/03/11	PRICE SENSITIVE	43.09KB	Share
BNOHalf Yearly Report and Accounts
11/02/11	PRICE SENSITIVE	752.24KB	Share
BNOPatent Applications Filed on Compounds to Treat Memory Loss
04/02/11	PRICE SENSITIVE	37.63KB	Share
BNOAppendix 4C - quarterly
31/01/11	PRICE SENSITIVE	16.66KB	Share
BNOOpen Briefing - CEO on Company Update and BNC210 Results
25/11/10	PRICE SENSITIVE	191.13KB	Share
BNOInvitation to tender for the purchase of 27.76% of shares
10/11/10	PRICE SENSITIVE	90.78KB	Share
BNOAppendix 4C - quarterly
27/10/10	PRICE SENSITIVE	16.18KB	Share
BNOBNC210 - European Approval Granted for Two Phase Ib Trials
05/10/10	PRICE SENSITIVE	67.55KB	Share
BNOOpen Briefing - BNO CEO on BNC210 Clinical Trials
02/09/10	PRICE SENSITIVE	191.58KB	Share
BNOBNC210 Data Presented at Leading European Forum
30/08/10	PRICE SENSITIVE	61.64KB	Share
BNOFull Year Statutory Accounts
19/08/10	PRICE SENSITIVE	81.95KB	Share
BNOAppendix 4C - quarterly
19/07/10	PRICE SENSITIVE	17KB	Share
BNOBNC210 Phase I Trial Successful
21/06/10	PRICE SENSITIVE	69.67KB	Share
BNOBionomics Presents BNC105 Clinical Data at ASCO
07/06/10	PRICE SENSITIVE	36.59KB	Share
BNOOpen Briefing - CEO on Merck Serono Extension
25/05/10	PRICE SENSITIVE	223.72KB	Share
BNOMerck Serono Agreement Extended
24/05/10	PRICE SENSITIVE	35.05KB	Share
BNOSecond BNC210 Phase I Clinical Trial Commences
06/05/10	PRICE SENSITIVE	37.71KB	Share
BNOAppendix 4C - quarterly
21/04/10	PRICE SENSITIVE	17KB	Share
BNONew BNC105 Data Presented at International Cancer Conference
16/04/10	PRICE SENSITIVE	38.1KB	Share
BNOOpen Briefing - CEO on Clinical Trials Update
31/03/10	PRICE SENSITIVE	191.87KB	Share
BNOBNC105 Phase II Mesothelioma Clinical Trial Starts
26/03/10	PRICE SENSITIVE	39.57KB	Share
BNOBNC210 Clinical Trial Results
02/03/10	PRICE SENSITIVE	49.35KB	Share
BNOHalf Yearly Report and Accounts
18/02/10	PRICE SENSITIVE	1.36MB	Share
BNOPositive New BNC210 Data
02/02/10	PRICE SENSITIVE	1011.93KB	Share
BNOAppendix 4C - quarterly
28/01/10	PRICE SENSITIVE	16.95KB	Share
BNOBNC105 US Renal Cancer Trial Initiated
27/01/10	PRICE SENSITIVE	40.07KB	Share
BNOOpen Briefing - BNC105 Phase II Trial for Mesothelioma
22/12/09	PRICE SENSITIVE	227.91KB	Share
BNOBNO to Conduct Phase II Trial in Mesothelioma
09/12/09	PRICE SENSITIVE	36.98KB	Share
BNOAppendix 4C - quarterly
29/10/09	PRICE SENSITIVE	80.91KB	Share
BNOFirst Stage of BNC210 Clinical Trial Successfully Completed
27/10/09	PRICE SENSITIVE	35.89KB	Share
BNOLatest BNC210 Data To Be Presented In US
16/10/09	PRICE SENSITIVE	180.05KB	Share
BNOCEO Open Briefing
17/09/09	PRICE SENSITIVE	59.64KB	Share
BNOReinstatement to Official Quotation
08/09/09	PRICE SENSITIVE	8.03KB	Share
BNO$15 Million Capital Raising
08/09/09	PRICE SENSITIVE	34.63KB	Share
BNOSuspension from Official Quotation
07/09/09	PRICE SENSITIVE	17.49KB	Share
BNOTrading Halt
03/09/09	PRICE SENSITIVE	20.63KB	Share
BNOPreliminary Final Report - Appendix 4E
28/08/09	PRICE SENSITIVE	76.16KB	Share
BNOAppendix 4C - quarterly
29/07/09	PRICE SENSITIVE	79.39KB	Share
BNOOpen Briefing - BNO CEO on Milestones Achieved
02/07/09	PRICE SENSITIVE	63.12KB	Share
BNOBNO - US Clinical Trial of BNC105 in Renal Cell Cancer
02/07/09	PRICE SENSITIVE	28.28KB	Share
BNOBNC210 Phase I Clinical Trial Initiated
25/06/09	PRICE SENSITIVE	36.81KB	Share
BNOOpen Briefing BNC105 Interim Data
29/05/09	PRICE SENSITIVE	59.92KB	Share
BNOInitial Data from BNC105 Phase I Clinical Trial Presented
29/05/09	PRICE SENSITIVE	25.46KB	Share
BNOBNO Anxiety Drug Candidate Approved to Enter Human Trial
21/05/09	PRICE SENSITIVE	25.85KB	Share
BNOOpen Briefing - New Data on BNC105
22/04/09	PRICE SENSITIVE	58.2KB	Share

REFRESH

First 2 3

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

BIONOMICS LIMITED - Announcements

Announcements

Clean energy vehicles with hydrogen production and distribution all under one roof

Prospect Resources continues to advance Mumbezhi project

Leeuwin Metals set to unlock significant gold potential at Marda

Haranga Resources: From uranium in Senegal to gold in the US

Top Stories